Hardean Achneck - Oct 8, 2024 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Chief Medical Officer
Signature
/s/ Lesley Ann Calhoun, as attorney-in fact for Hardean Achneck
Stock symbol
ALGS
Transactions as of
Oct 8, 2024
Transactions value $
$0
Form type
4
Date filed
10/10/2024, 04:16 PM
Previous filing
Sep 26, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +75K $0.00 75K Oct 8, 2024 Common Stock 75K $7.32 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty Five Percent (25%) of the shares subject to the option will vest on September 23, 2025 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.